Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: Doug Bean who wrote (1145)	4/28/1999 4:47:00 PM
From: muddphudd	Respond to of 1837

Maybe the stock is just responding to the general pounding the pharmaceuticals and biotechs have been taking for the last few weeks. Big names like Merkc, Pfizer, Schering, are all way down from their highs of a few weeks ago. Tech stocks are also hurting today.

To: Doug Bean who wrote (1145)	4/28/1999 5:56:00 PM
From: vestor	Read Replies (1) \| Respond to of 1837

Still here...... This is the quiet period ......I do expect movement in late May as nationwide advertising starts...... meanwhile we await..... Considering how the drug sectors been doing we are actually doing quite well .... Although we may not make much progress over the next three weeks the downside risk appears minimal and if it happens a great buying opp.......

To: Doug Bean who wrote (1145)	4/28/1999 7:39:00 PM
From: Thure Meyer	Respond to of 1837

Doug, Its only been a month since Duramed got approval. Lets give these guys a break. If you look on their web site you will find an outline of the marketing plan, I quote: " Cenestin Marketing Campaign Duramed has been working aggressively in the months leading up to the approval of Cenestin to plan for a comprehensive product launch. Duramed will be working closely with Cardinal over the next 12-14 weeks to ensure that all aspects of the product rollout are in place. These steps include distributing product to pharmacies and arranging for face-to-face visits with physicians, as well as initiating a comprehensive advertising program," Arington noted. "Cardinal MarketFORCE will use its expertise to establish a high-quality sales force within a short period of time. We're pleased because we will work with them to ensure that the force is one that can grow as we accelerate our branded product efforts over the next several years." Duramed and Cardinal noted that Cardinal MarketFORCE's management team has built a number of contract sales forces in the past, ranging in size from 25 to 400 people. The Cardinal team includes: - Don Wetherhold, president, with extensive experience in hormone replacement sales and marketing and two years with the second largest contract sales and marketing organization in the world. - Thomas Dimke, vice president of operations, one of two individuals who organized the U.S. roll-out of the largest contract sales and marketing organization in the world, and also spent 12 years at Ciba-Geigy in a variety of capacities, including executive regional director of sales, working in the women's health and hormone replacement areas. - Bruce Ward, vice president of sales, who was with the Ross Division of Abbott Laboratories for 14 years, which marketed a variety of products to obstetricians and gynecologists. ..."" You will note that the milestone for the rollout campaign is 12-14 weeks from March 30th. That puts us in June, also they will be advertising. I think we should relax a bit and give them another month or so. Heck, I know you waited 12 months the last time, what's 12 weeks to a guy with nerves of steel and ice water in his veins. thure